期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
非小细胞肺癌免疫检查点抑制剂治疗相关外周血生物标志物研究进展 被引量:5
1
作者 王鹏 汤传昊 梁军 《中国肺癌杂志》 CAS CSCD 北大核心 2021年第7期503-512,共10页
以免疫检查点抑制剂(immune checkpoint inhibitors, ICI)为代表的免疫治疗改变了非小细胞肺癌(non-small cell lung cancer, NSCLC)的治疗模式,标志物指导下的免疫治疗是精准治疗的关键。基于组织的程序性死亡受体配体1(programmed cel... 以免疫检查点抑制剂(immune checkpoint inhibitors, ICI)为代表的免疫治疗改变了非小细胞肺癌(non-small cell lung cancer, NSCLC)的治疗模式,标志物指导下的免疫治疗是精准治疗的关键。基于组织的程序性死亡受体配体1(programmed cell death ligand 1, PD-L1)和肿瘤突变负荷(tumor mutational burden, TMB)是临床上广泛接受的用于指导免疫治疗的生物标志物,然而组织标本不易获取且难以克服肿瘤的时空异质性。外周血标志物作为组织检测的补充,具有取材方便、无创等优势,同时可涵盖肿瘤和宿主免疫状态两方面的信息,在NSCLC免疫治疗疗效预测及治疗反应动态监测方面的价值日益凸显。本文总结NSCLC免疫检查点抑制剂治疗相关外周血生物标志物的研究进展,旨在为开发新型的生物标志物提供参考。 展开更多
关键词 外周血标志物 免疫检查点抑制剂 肺癌 免疫治疗
在线阅读 下载PDF
血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析 被引量:9
2
作者 陈含笑 杨雪 +10 位作者 刘慧君 马琨 仲佳 董智 卓明磊 王玉艳 李俭杰 安彤同 吴梅娜 王子平 赵军 《中国肺癌杂志》 CAS CSCD 北大核心 2017年第9期589-597,共9页
背景与目的表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)在EGFR突变型肺腺癌人群中能显著提高生存,从而改变了晚期肺癌的治疗模式,但并不是所有EGFR敏感突变者均能从EGFR... 背景与目的表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)在EGFR突变型肺腺癌人群中能显著提高生存,从而改变了晚期肺癌的治疗模式,但并不是所有EGFR敏感突变者均能从EGFR-TKIs治疗中获益。本研究欲通过外周血肿瘤标志物的检测对突变型肺腺癌患者的靶向治疗进行预测及指导。方法回顾性分析2009年6月-2014年6月于北京大学肿瘤医院胸部肿瘤内一科一线接受EGFR-TKIs治疗的EGFR突变型IIIb期-IV期肺腺癌患者的临床资料,分析其基线肿瘤标志物与EGFR-TKIs疗效及生存的关系。结果总体人群客观有效率(objective response rate,ORR)52.8%,疾病控制率(disease control rate,DCR)89.3%。基线癌胚抗原(carcino-embryonic antigen,CEA)水平升高者对EGFR-TKIs疗效更佳(ORR 61.3%vs35.9%,DCR 95.2%vs 74.4%,P<0.001),治疗1个月后CEA、细胞角蛋白19片段(cytokeratin 19 fragments,CYFRA21-1)以及CA125水平下降者有效率更高(ORR分别是61.5%vs 25%,P=0.002;58.5%vs 37.5%,P=0.004;61.8%vs 20%,P=0.027)。生存分析中,基线CEA水平正常者较高水平者无进展生存期(progression-free survival,PFS)明显缩短(中位PFS 5.9个月vs 9.8个月,P=0.027),而基线CYFRA21-1、CA125水平升高者PFS明显缩短(中位PFS 9.0个月vs11.4个月,P=0.029;9.0个月vs 11.5个月,P=0.023)。多因素分析显示,美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)评分0-1分、基线CYFRA21-1正常水平、治疗1月后CEA下降阳性患者PFS更长。总生存期(overall survival,OS)与CYFRA21-1、CA125升高有关(中位OS分别为25.1个月vs 52.5个月,P=0.003;22.7个月vs55.0个月,P<0.001),而多因素分析中总生存与CEA下降有关(P=0.046)。结论治疗前高水平CEA以及治疗后CEA下降可以预测晚期肺腺癌患者一线接受EGFR-TKIs的疗效,而治疗前高水平CYFRA21-1以及CA125则预示着生存期缩短。 展开更多
关键词 外周血肿瘤标志 肺肿瘤 EGFR酪氨酸激酶抑制剂 疗效 生存
在线阅读 下载PDF
Insights on Peripheral Blood Biomarkers for Parkinson’s Disease
3
作者 刘经凯 LI Yu-Meng +2 位作者 LIU Jing-Kai CHEN Zi-Xuan DENG Yu-Lin 《生物化学与生物物理进展》 北大核心 2025年第1期72-87,共16页
Parkinson’s disease(PD)is a common neurodegenerative disorder with profound impact on patients’quality of life and long-term health,and early detection and intervention are particularly critical.In recent years,the ... Parkinson’s disease(PD)is a common neurodegenerative disorder with profound impact on patients’quality of life and long-term health,and early detection and intervention are particularly critical.In recent years,the search for precise and reliable biomarkers has become one of the key strategies to effectively address the clinical challenges of PD.In this paper,we systematically evaluated potential biomarkers,including proteins,metabolites,epigenetic markers,and exosomes,in the peripheral blood of PD patients.Protein markers are one of the main directions of biomarker research in PD.In particular,α‑synuclein and its phosphorylated form play a key role in the pathological process of PD.It has been shown that aggregation ofα-synuclein may be associated with pathologic protein deposition in PD and may be a potential marker for early diagnosis of PD.In terms of metabolites,uric acid,as a metabolite,plays an important role in oxidative stress and neuroprotection in PD.It has been found that changes in uric acid levels may be associated with the onset and progression of PD,showing its potential as an early diagnostic marker.Epigenetic markers,such as DNA methylation modifications and miRNAs,have also attracted much attention in Parkinson’s disease research.Changes in these markers may affect the expression of PD-related genes and have an important impact on the onset and progression of the disease,providing new research perspectives for the early diagnosis of PD.In addition,exosomes,as a potential biomarker carrier for PD,are able to carry a variety of biomolecules involved in intercellular communication and pathological regulation.Studies have shown that exosomes may play an important role in the pathogenesis of PD,and their detection in blood may provide a new breakthrough for early diagnosis.It has been shown that exosomes may play an important role in the pathogenesis of PD,and their detection in blood may provide new breakthroughs in early diagnosis.In summary,through in-depth evaluation of biomarkers in the peripheral blood of PD patients,this paper demonstrates the important potential of these markers in the early diagnosis of PD and in the study of pathological mechanisms.Future studies will continue to explore the clinical application value of these biomarkers to promote the early detection of PD and individualized treatment strategies. 展开更多
关键词 Parkinson’s disease peripheral blood biomarkers early diagnosis
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部